


Sanyou Bio and Yugong Bio team up to accelerate expansion in high-end synthetic enzyme market

12 November 2025 | News

Injects fresh momentum into the high-quality development of China's biopharmaceutical industry



China-based startups Sanyou Bio and Yugong Bio have announced the signing of a strategic cooperation agreement. This powerful alliance marks a significant step to deepen their collaboration in the development of high-end synthetic molecular enzymes.

This collaboration is based on a strong mutual consensus: Sanyou Bio possesses profound expertise in innovative biopharmaceutical discovery and development, while Yugong Bio holds core advantages in enzyme engineering and large-scale production. This powerful alliance will focus on the entire chain of enzyme product R&D, production, and application.

By seamlessly integrating their respective superior resources, the partners aim to jointly overcome key technological bottlenecks in the biopharmaceutical field, committed to driving cost reduction, efficiency improvement, and technological innovation across the industry. This forward-looking strategic layout not only marks a new phase for the collaboration but also injects fresh momentum into the high-quality development of China's biopharmaceutical industry.

Sanyou Bio will utilise its trillion-scale molecular library and efficient screening platform to support Yugong Bio's enzyme optimization and engineering for specific application scenarios. Yugong Bio will leverage its mature enzyme product R&D and large-scale production system to ensure the quality and stable supply of co-developed products. This integrated "Discovery + Optimisation + Production" model will greatly accelerate the R&D industrialization process.

Through joint R&D and supply chain coordination, the partners aim to develop enzyme preparations and solutions with superior performance and lower cost. This will not only help reduce the R&D and production costs for both parties but also provide more cost-effective products for downstream customers, especially in fields like biopharmaceutical R&D and in vitro diagnostics, enhancing their market competitiveness.